MariMed Inc.

As of June 30, 2026, MariMed Inc carries a market capitalization of 38.08M, placing it among publicly traded companies globally. Its enterprise value stands at 152.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MariMed Inc's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, MariMed Inc has 401.17M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.16, and the price-to-book ratio stands at 0.59.

As of June 30, 2026, MariMed Inc trades at an EV/EBITDA multiple of 11.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 152.09M versus a market cap of 38.08M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MariMed Inc maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 209.69, indicating elevated leverage, while an interest coverage ratio of 1.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MariMed Inc posted a negative return on equity (ROE) of -28.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.45, reflecting losses generated across the asset base. The company generates approximately 258,256.02 in revenue per employee across its workforce of 900.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.79 indicates how many times MariMed Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, MariMed Inc recorded 6.73M in income tax expense. The company reported a pretax loss of -14.45M and -21.22M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, MariMed Inc's stock has declined approximately 64.29% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.13.

Over the twelve months ended June 30, 2026, MariMed Inc generated 232.49M in revenue and converted that into -21.22M in net income, yielding earnings per share of -0.05. EBITDA reached 13.20M, while operating income came in at -1.91M.

As of June 30, 2026, MariMed Inc holds 11.97M in cash and equivalents against 128.69M in total debt, resulting in a net debt position of 99.88M. Total book value stands at 64.08M, with working capital of -7.55M providing operational flexibility.

MariMed Inc produced 13.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.85M in capital expenditures, free cash flow totaled 10.31M - equivalent to 0.03 per share.

Over the twelve months ended June 30, 2026, MariMed Inc posted a gross margin of 35.63, reflecting its pricing power and cost economics. The operating margin of -0.82 and net profit margin of -9.13 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, MariMed Inc paid dividends of 0.00 per share. The dividend payout ratio of -0.91 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 27.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 18.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MariMed Inc shareholders.

As of June 30, 2026, MariMed Inc has an Altman Z-Score of -0.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.